Foundation series

Medtech Company, Strados Labs, Receives National Science Foundation SBIR Phase II Grant

The Strados RESP smart sensor platform for respiratory health is the first technology of its kind, providing real-time access to key changes in lung acoustics and breathing patterns that go far beyond measuring cough.

This award follows key business milestones including a pre-Series A funding round of $4.5M and obtaining CE marking in late 2021. The funding will help further validate the RESP platform, improve algorithm performance, and expand the platform’s marketing claims to enable processing early and at a lower cost of chronic cardiopulmonary diseases and infectious diseases in remote care facilities. through telehealth.

Delmonico adds: “This grant will be used in the further development of a standardized database for things like wheezology and coughology. [acoustic biomarkers] to predict disease progression and personalize care.

The current standard of care relies on intermittent monitoring with a stethoscope by a qualified healthcare professional, which raises significant inter-user variability in the assessment and classification of lung sounds. RESP allows for extended monitoring and archiving of pulmonary acoustic signals for later evaluation and is also an invaluable remote monitoring tool for researchers conducting clinical trials of new drugs for respiratory and chronic diseases.

About Strados Laboratories

Strados Labs is a medical technology company that develops smart sensor platforms that use machine learning and proprietary algorithms to detect and predict aggravating conditions associated with serious chronic respiratory diseases to improve the lives of patients around the world. The company has developed a first-of-its-kind smart sensor platform for respiratory health, RESP™. Strados recently obtained CE marking for RESP™ and received its FDA Class II 510(k) clearance last December. The Company is developing a robust pipeline algorithm to support and treat other chronic diseases, as well as chronic disease management pathways. Strados will continue to target asthma, COPD and respiratory infectious diseases (COVID, RSV, etc.) heading into 2022, with plans to add heart failure and pediatrics in late 2022. The company is based in philadelphia cream and is a private company. For more information visit:

About NSF Small Business Programs

America’s Seed Fund, powered by the NSF, rewards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working in almost any field of science and technology can receive up to $2 million to support research and development, helping to eliminate technological risks for commercial success. America’s Seed Fund is mandated by Congress under the Small Business Innovation Research program. The NSF is an independent federal agency with a budget of approximately $8.5 billion which supports fundamental research and education in all fields of science and engineering. For more information, visit

Media Contact:
Inspire Agency (formerly B Squared)
Lauren Lorow
[email protected]

SOURCE Strados Labs